On August 28, 2019 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, reported that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate at the following healthcare conferences in September (Press release, CytomX Therapeutics, AUG 28, 2019, View Source [SID1234539056]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 14ᵗʰ Annual Biotech Conference
Panel Discussion: New Targets in Cancer Immunotherapy and the Tumor Microenvironment
Date: Wednesday, September 4, 2019
Time: 9:30 a.m. ET
Location: Boston, Massachusetts

H. C. Wainwright 21st Annual Global Investment Conference
Date: Tuesday, September 10, 2019
Time: 10:50 a.m. ET
Location: New York, New York
Live audio webcast of the panel discussion and corporate presentation will be available through the "Investors & News" section of CytomX’s website. An archived replay will be available for 60 days following the event.

On August 28, 2019 Clovis Oncology, Inc. (Nasdaq: CLVS) reported that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019 at 8:35 AM Eastern Time (Press release, Clovis Oncology, AUG 28, 2019, View Source [SID1234539055]). The conference will be held at the Westin Copley Place in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

On August 28, 2019 Cerus Corporation (Nasdaq: CERS) reported that the Company will participate in two upcoming investor conferences (Press release, Cerus, AUG 28, 2019, View Source [SID1234539054]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present at the Baird 2019 Global Healthcare Conference on Wednesday, September 4, 2019, at 12:15 p.m. EDT. The conference will be held at the InterContinental New York Barclay in New York City.
William ‘Obi’ Greenman and Kevin D. Green, Cerus’ vice president finance and chief financial officer, are scheduled to present at 17th Annual Morgan Stanley Healthcare Conference on Monday, September 9, 2019, at 1:05 p.m. EDT. The conference will be held at the Grand Hyatt New York in New York City.
Live webcasts of the presentations will be available on the Investor Relations page of the Cerus web site at View Source Replays of the presentations will be available for approximately two weeks following the completion of the events.

On august 28, 2019 Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, reported that senior management will participate in three upcoming healthcare investor conferences (Press release, Bellicum Pharmaceuticals, AUG 28, 2019, View Source [SID1234539053]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

2019 Wells Fargo Securities Healthcare Conference
Date/Time: Wednesday, September 4, 2019 at 3:35 p.m. EDT
Location: Boston

Citi’s 14th Annual Biotech Conference
Date: Thursday, September 5, 2019 (one-on-one investor meetings)
Location: Boston

Ladenburg Thalmann 2019 Healthcare Conference
Date/Time: Tuesday, September 24, 2019 at 11:30 a.m. EDT
Location: New York

Live webcasts of the presentations at the Wells Fargo and Ladenburg Thalmann conferences may be accessed from the News & Events section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.

On August 28, 2019 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, reported that the FDA has accepted the company’s IND filing for AGEN1223, a milestone in its partnership with Gilead Sciences, Inc (Press release, Agenus, AUG 28, 2019, View Source [SID1234539051]). This milestone triggers a cash payment of $7.5M.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This announcement represents the third milestone delivered in our collaboration with Gilead this year," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "AGEN1223 is a first-in-class bispecific designed to selectively deplete immune-suppressing cells (regulatory T cells) from the tumor microenvironment while boosting cancer-fighting effector T cells and sparing important peripheral regulatory T cells – an important mechanism not addressed with current therapies."

The collaboration between the two companies was announced in December 2018. Under the terms of the agreement, Agenus received $150 million in upfront cash payment and equity investment and is eligible for approximately $1.7 billion in future fees and milestones.

AGEN1223 is an investigational agent that has not been approved for any uses. Efficacy and safety have not been established.